Leap Therapeutics Inc. (LPTX)
Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 38.32M shares outstanding. The number of shares has increased by 49.68% in one year.
| Shares Outstanding | 38.32M |
| Shares Change (YoY) | 49.68% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 33% |
| Shares Floating | 28.57M |
| Failed to Deliver (FTD) Shares | 905 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 1.01M, so 2.63% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short % of Shares Out | 2.63% |
| Short % of Float | 3.53% |
| Short Ratio (days to cover) | 2.68 |
Valuation Ratios
The PE ratio is -1.04 and the forward PE ratio is -0.51. Leap Therapeutics's PEG ratio is 0.06.
| PE Ratio | -1.04 |
| Forward PE | -0.51 |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -1.93 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Leap Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.64, with a Debt / Equity ratio of 0.
| Current Ratio | 5.64 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.43 |
| Cash Flow / Debt | -167 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.35% and return on capital (ROIC) is -144.1%.
| Return on Equity (ROE) | -1.35% |
| Return on Assets (ROA) | -1.12% |
| Return on Capital (ROIC) | -144.1% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,507,666.67 |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.75% in the last 52 weeks. The beta is 0.14, so Leap Therapeutics's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -83.75% |
| 50-Day Moving Average | 1.8 |
| 200-Day Moving Average | 2.4 |
| Relative Strength Index (RSI) | 18.75 |
| Average Volume (20 Days) | 800.56K |
Income Statement
| Revenue | n/a |
| Gross Profit | -427K |
| Operating Income | -87.04M |
| Net Income | -81.41M |
| EBITDA | -80.99M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.98 |
Balance Sheet
The company has 70.64M in cash and 262K in debt, giving a net cash position of 70.38M.
| Cash & Cash Equivalents | 70.64M |
| Total Debt | 262K |
| Net Cash | 70.38M |
| Retained Earnings | -399.58M |
| Total Assets | 65.05M |
| Working Capital | 47.72M |
Cash Flow
In the last 12 months, operating cash flow was -43.75M and capital expenditures 0, giving a free cash flow of -43.75M.
| Operating Cash Flow | -43.75M |
| Capital Expenditures | 0 |
| Free Cash Flow | -43.75M |
| FCF Per Share | -2.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -865.22% |
| FCF Yield | -246.14% |
Analyst Forecast
The average price target for LPTX is $8.5, which is 1747.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 1747.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jun 21, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -11.55 |
| Piotroski F-Score | 2 |